33results about How to "Preventing and treating" patented technology

The present invention relates to a first group of novel viral and human associated oligonucleotides, here identified as “Genomic Address Messenger” or “GAM” oligonucleotide, and a second group of novel operon-like viral and human polynucleotides, here identified as “Genomic Record” or “GR” polynucleotide. GAM oligonucleotides selectively inhibit translation of known “target” genes, many of which are known to be involved in various viral diseases. Nucleic acid molecules are provided respectively encoding 1,655 viral and 105,537 human GAM precursor oligonucleotides, and 190 viral and 14,813 human GR polynucleotides, as are vectors and probes both comprising the nucleic acid molecules, and methods and systems for detecting GAM oligonucleotides and GR polynucleotides and specific functions and utilities thereof, for detecting expression of GAM oligonucleotides and GR polynucleotides, and for selectively enhancing and selectively inhibiting translation of the respective target genes thereof.

Antiviral compositions comprising a modified nuclease, or a plurality of such modified nucleases having at least one non-natural amino acid residue substituted for a naturally occurring amino acid in a parent nuclease are provided, as are methods of use and kits providing unit dosages of such compositions.

The present invention relates to a probiotic preparation for preventing and treating canine gastrointestinal disorders containing at least two dog-specific strains of lactic acid bacteria belonging to genus Lactobacillus, a calcium source in an amount of 20-99 weight-% expressed as CaCO₃ of the dry weight of the preparation, and at least one prebiotic, and optionally additional dog-specific strains of lactic acid bacteria, excipients and carriers. The invention further relates to a process for the manufacture of the probiotic preparation, to dog food comprising the probiotic preparation, and to the use of the probiotic preparation for the manufacture of a pharmaceutical product or a dog food product for preventing and treating canine gastrointestinal disorders.

The present invention includes compositions comprising one or more complement inhibitors and one or more CD14 pathway inhibitors for the prevention or treatment of sepsis. The complement inhibitors may be antibodies that bind to and inhibit complement proteins such as C5a and the CD14 pathway inhibitors may be antibodies that bind to and inhibit CD14 pathway components, such as CD14 and LPS. The invention also relates to methods of treating subjects suffering from sepsis comprising administering these compositions, as well as kits for supplying the compositions for treatment.

The present invention relates generally to methods of preventing or treating toxicities of the skin, hair, and/or nails, which are associated with administration of one or more epidermal growth factor receptor inhibitors, with light-emitting diode photomodulation treatment, either alone or in combination with other agents.

A pharmaceutical preparation for treating connective tissue damage in man and in animals, comprising a therapeutically effective amount of a glycosaminoglycan composition comprising chondroitin sulfate, N-acetyl D-glucosamine, and hyaluronan, in combination with isolated stem cells. Methods of use and kits containing the glycosaminoglycan composition and materials for isolating stem cells and for treating connective tissue damage and repair of cartilage in man and in animals are also provided.

Provided by the invention are systems for applying diaper rash treatment compositions to a selected skin treatment area without the need for the person administering the treatment to directly contact the composition or the skin of the patient. Application of the diaper rash treatment composition is accomplished by forming the composition into a mist or spray using an atomizing spray dispenser.

The use of monoclonal antibodies specific for respiratory syncytial virus (RSV). Specifically, to a monoclonal antibody IgG2A secreted by the cell line of 8A4/G9 hybridoma specifically directed to the M2-1 viral antigen, which is associated with the nucleocapside of the virus. The antibodies can be used for assays for the detection and/or determination of RSV infection. The antibodies are in the pure state and do not contain any other contaminating biological material. A method for preventing and treating the infection caused by respiratory syncytial virus (RSV) in a given host is provided, including the administration of a composition containing the monoclonal antibodies secreted by the 8A4/G9 hybridoma in sufficient doses to prevent the disease. The antibody can be humanized in order to minimize the possibility of an immune response against the same in the patient. In addition, it can be used to obtain any pharmaceutical form of the formulation of the monoclonal antibodies secreted by the 8A4/G9 hybridoma, which are suitable for the treatment or prevention of the disease caused by RSV. It also provides methods for detection and diagnosis of RSV viral antigens in biological samples using the monoclonal antibodies produced and secreted by cells of the 8A4/G9 hybridoma.

The present invention provides an application of a periplaneta americana medicinal powder or a periplaneta americana extract in preparation for a medicine used for preventing and treating radiation-induced damages. The medicine is capable of preventing and treating the damages caused by radiation therapy for nasopharyngeal cancer, esophageal cancer, stomach cancer, lung cancer, liver cancer, breast cancer, waldeyer's lymphoma, and other cancers. Through test verification, the medicine of the present invention has an obvious prevention and treatment effect for damages caused by radiation therapy for patients with breast tumours and breast cancer after surgery.

The invention relates to the use of microbes Lactobacillus rhamnosus LGG, ATCC 53103, Latobacillus rhamnosus LC705, DSM 7061, and Propionibacterium freudenreichii ssp. shermanii PJS, DSM 7067 in inhibiting yeast growth, for preventing and treating diseases caused by yeast and for relieving yeast-related symptoms in animals or humans.

GABA analogs such as gabapentin and pregabalin are useful to prevent and treat inflammatory diseases.

An object of the present invention is to establish a method that enables safe and convenient large-scale preparation of regulatory dendritic cells. The present invention provides a method for preparing regulatory dendritic cells, which comprises culturing cells that can be induced to result in regulatory dendritic cells in the presence of a [1,2,4]triazolo[1,5-a]pyrimidine derivative.

The present document describes apple peel polyphenolic extract comprising a proanthocyanidin content of at least 15000 μg/g of dry weight, comprising about 30% to about 35% epicatechin content, and pharmaceutical composition comprising the apple peel polyphenolic extract. The present document also describes methods and use of the apple peel polyphenolic extract for preventing or treating conditions such as oxidative stress, inflammation and mitochondrial dysfunction of the liver, insulin resistance, intestinal endothelial tissue injury, non-alcoholic fatty liver disease, non-alcoholic steatohepatitis (NASH), liver fibrosis, liver cirrhosis, and/or inhibition of de novo lipogenesis and β-oxidation of free fatty acids for preventing accumulation thereof in the liver. The present document also describes a process for extraction of at least a polyphenol content from dry apple peel powder.

The preset invention relates to a method for treating lupus erythematosus, particularly lupus nephritis, comprising administering a subject in need thereof a therapeutically effective amount of epigallocatechin-3-gallate (EGCG) or a pharmaceutically acceptable salt or a physiologically functional derivative, together with one or more pharmaceutically acceptable carriers, diluents or excipients.

The present invention inter alia relates to a method of promoting collateral circulation comprising the step of exposing a subject to a therapeutically effective amount of an NO donor wherein the therapeutically effective amount of the NO donor promotes arteriogenesis sufficient to augment collateral circulation in a physiological or pathological condition.

The present invention relates to a pharmaceutical composition for prevention or treatment of neurodegenerative disease, a composition employing amlexanox, which has been verified for safety through clinical trials. In addition, the present invention relates to a pharmaceutical composition for prevention or treatment of amyloid beta-caused cell damage, the composition employing a phosphodiesterase (PDE) inhibitor inclusive of amlexanox. The composition of the present invention can be advantageously and safely used for ameliorating or treating amyloid beta-caused neurodegenerative disease and cell damage, without worry about side effects.

In a first aspect, the present invention relates to new compounds based on diphenylpiperazine and diphenylpiperidine structures. In particular, the present invention provides new flunarizine derivatives having improved hepaci virus infection inhibitory activity. In a further aspect, the present invention relates to a pharmaceutical composition containing said compound as well as the use of said pharmaceutical composition and the compounds according to the present invention in preventing or treating hepaci virus infection, in particular, HCV virus infection, like HCV of genotype 2. Moreover, a method for determining effectiveness of prophylactic or therapeutic treatment of hepaci virus, like HCV infection as well as a method for determining the therapy regimen of an individual afflicted with hepaci vims infection including HCV infection is provided. Said method is based on determining the sequence or interfacial hydrophobicity of the hepaci virus E1 protein. This may include determining the presence of mutations at predetermined positions of the E1 sequence. Based on determining the interfacial hydrophobicity of the E1 protein, the sensitivity to a diphenylpiperazine or diphenylpiperidine based hepaci virus inhibitor as well as a phenothiazine and cycloheptenepiperidine based hepaci virus inhibitor can be determined. When the central hydrophobicity region is disrupted or the hydrophobicity is below zero applying the Wimley-White hydropathy plot, or the mutations at positions 290, 299, 301 and 310 of SEQ ID No. 1 are present, it is submitted that the sensitivity against said compounds is reduced. Hence, it is possible to determine the therapy regimen of an individual afflicted with hepaci virus infection or being a risk of being afflicted with hepaci vims infection, in particular HCV infection like HCV genotype 2 infection.

The objective of the present invention is to develop and provide: a composition that more inexpensively and safely augments plant disease resistance and/or plant branching by inducing new plant disease resistance via a brassinosteroids; and a method for suppressing microbial infection of plants and a method for augmenting branching using the composition. Provided is a composition containing as the active ingredient a peptide hormone obtained on the basis of isolating a disease resistant brassinosteroid variant and analyzing the causative gene thereof.

Provided is a use of Dendropanax morbifera extract as an agent for preventing and treating benign prostatic hyperplasia, and more particularly, a composition for preventing and treating benign prostatic hyperplasia and a functional health food for preventing and reducing the effects of benign prostatic hyperplasia, in which the composition and food include, as an active ingredient, a Dendropanax morbifera extract or a compound which is isolated from the extract and then purified. The Dendropanax morbifera extract and the compound isolated from the extract have been demonstrated to be capable of effectively preventing and treating benign prostatic hyperplasia through a mechanism for inhibiting the androgen receptor signaling that induces benign prostatic hyperplasia. Therefore, the Dendropanax morbifera extract and the compound isolated from the extract according to the present invention can be effectively used in the production of medicines and functional foods capable of preventing, treating, and reducing the effects of benign prostatic hyperplasia and prostate cancer.

The present invention is intended to clarify the relationship between PAR-2 and cerebral infarction and thereby provide an efficient method of preventing and treating cerebral infarction, as well as a pharmaceutical composition therefore. Namely, the present invention relates to a method of preventing and treating cerebral infarction by activating PAR-2 and/or promoting expression of PAR-2 gene. The present invention further relates to a pharmaceutical composition for preventing and treating cerebral infarction, comprising one, or two or more of the active ingredients selected from the group consisting of a PAR-2 activator and/or a PAR-2 gene expression promoter; as well as a pharmaceutically acceptable carrier. It further relates to a method of screening an active ingredient for preventing and treating cerebral infarction using as an indicator the PAR-2 activation promoted by a test substance.